ICUI Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -0.63% compared to ICU Medical, Inc.'s net margin of -12425.36%. ICU Medical, Inc.'s return on equity of -0.36% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

ICU Medical, Inc. has a consensus price target of $180.83, signalling upside risk potential of 27.03%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than ICU Medical, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than ICU Medical, Inc..

ICU Medical, Inc. has a beta of 0.823, which suggesting that the stock is 17.719% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $537.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. ICU Medical, Inc.'s net income of -$3.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.51x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of -0.63% compared to ICU Medical, Inc.'s net margin of 7.22%. ICU Medical, Inc.'s return on equity of -0.36% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

ICU Medical, Inc. has a consensus price target of $180.83, signalling upside risk potential of 27.03%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.00 which suggests that it could grow by 22.2%. Given that ICU Medical, Inc. has higher upside potential than Merit Medical Systems, Inc., analysts believe ICU Medical, Inc. is more attractive than Merit Medical Systems, Inc..

ICU Medical, Inc. has a beta of 0.823, which suggesting that the stock is 17.719% less volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.504%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $537.7M, which are larger than Merit Medical Systems, Inc. quarterly revenues of $384.3M. ICU Medical, Inc.'s net income of -$3.4M is lower than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is -- while Merit Medical Systems, Inc.'s PE ratio is 43.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.51x versus 3.46x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TriSalus Life Sciences, Inc. has a net margin of -0.63% compared to ICU Medical, Inc.'s net margin of -93.47%. ICU Medical, Inc.'s return on equity of -0.36% beat TriSalus Life Sciences, Inc.'s return on equity of --.

ICU Medical, Inc. has a consensus price target of $180.83, signalling upside risk potential of 27.03%. On the other hand TriSalus Life Sciences, Inc. has an analysts' consensus of $11.36 which suggests that it could grow by 76.63%. Given that TriSalus Life Sciences, Inc. has higher upside potential than ICU Medical, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than ICU Medical, Inc..

ICU Medical, Inc. has a beta of 0.823, which suggesting that the stock is 17.719% less volatile than S&P 500. In comparison TriSalus Life Sciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TriSalus Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. TriSalus Life Sciences, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $537.7M, which are larger than TriSalus Life Sciences, Inc. quarterly revenues of $11.6M. ICU Medical, Inc.'s net income of -$3.4M is higher than TriSalus Life Sciences, Inc.'s net income of -$10.8M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is -- while TriSalus Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.51x versus 5.28x for TriSalus Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -0.63% compared to ICU Medical, Inc.'s net margin of 17.41%. ICU Medical, Inc.'s return on equity of -0.36% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

ICU Medical, Inc. has a consensus price target of $180.83, signalling upside risk potential of 27.03%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 21.72%. Given that ICU Medical, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe ICU Medical, Inc. is more attractive than West Pharmaceutical Services, Inc..

ICU Medical, Inc. has a beta of 0.823, which suggesting that the stock is 17.719% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ICU Medical, Inc. quarterly revenues are $537.7M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. ICU Medical, Inc.'s net income of -$3.4M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 42.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.51x versus 6.86x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.